ThromBio is a drug discovery company whose mission is to advance the global standard of care for the treatment of stroke using novel anti-thrombotic drugs with unprecedented safety and efficacy.

Leadership:
ThromBio’s programme is driven by international leaders in drug discovery & development, experimental biomedicine, global clinical trials capability and commercialisation.

Our Lead Candidate: TBO-309
TBO-309 represents an Australian drug development success story, that has resulted in a novel antiplatelet compound with truly remarkable properties.

Lead Indications:
Acute Ischaemic stroke remains the second largest cause of death and disability globally, with 85% of all strokes caused by blood clots that block blood flow to the brain.
TBO-309 is currently being trialled in patients in Phase II clinical trials, as an adjunct to thrombolysis (STARS).

Publications:
ThromBio’s technology is built around state-of-the-art science and technology, published by internationally recognised leaders in the field of drug discovery & and experimental biomedicine.

Media:
ThromBio’s technology has received global attention for its breakthrough scientific studies.

Contact us on social@thrombio.com.au or for more information look at our website.

ThromBio

Org chart

Teams

Offices

ThromBio

Org chart

Teams

Offices

Related companies